CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 293 enrolled
Drug / intervention
American ginseng +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00752895
NCT00752895Phase 2Completed

A Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients With Chronic Lymphocytic Leukemia

Wake Forest University Health Sciences·interventional·Posted Sep 16, 2008·Updated Sep 28, 2021

In Brief

A Phase 2 clinical trial evaluating American ginseng and Placebo for Leukemia. Completed, enrolled 293 participants across 125 sites.

Detailed Summary

RATIONALE: American ginseng extract may prevent or reduce acute respiratory illness in patients with chronic lymphocytic leukemia. It is not yet known whether American ginseng extract is more effective than a placebo in preventing respiratory infections. PURPOSE: This randomized trial is studying the side effects of American ginseng extract and to see how well it works compared with a placebo in preventing respiratory infection and in reducing antibiotic use in patients with chronic lymphocytic leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 16, 2008
Enrollment StartSep 1, 2008
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.8 years ago

Interventions

American ginsengdietary

Given orally

Placebodietary

Given orally